
Please try another search
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Arlene M. Morris | 71 | 2022 | Non-Executive Independent Chair |
Bryan L. Kobel | 42 | 2021 | CEO & Director |
A. James Culverwell | 68 | 2022 | Non-Executive Independent Director |
Martin E. Thorp | 71 | 2016 | CFO & Director |
Erin Adams | - | 2022 | Member of Scientific Advisory Board |
Uma Lakshmipathy | - | 2022 | Member of Scientific Advisory Board |
Chris Bond | - | 2022 | Member of Scientific Advisory Board |
Isabelle Riviere | - | 2022 | Member of Scientific Advisory Board |
Mark L. Bonyhadi | 70 | 2022 | Chairman of Scientific Advisory Board |
Blythe Sather | - | 2022 | Member of Scientific Advisory Board |
Daniel Olive | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review